| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Kazia Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.33 |
| 52 Week High | US$1.58 |
| 52 Week Low | US$0.19 |
| Beta | 2.1 |
| 11 Month Change | -9.19% |
| 3 Month Change | 47.30% |
| 1 Year Change | -68.25% |
| 33 Year Change | -97.09% |
| 5 Year Change | -90.99% |
| Change since IPO | -99.80% |
Recent News & Updates
Recent updates
Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy
Jul 06Kazia enters clinical collaboration with Cornell University for mid-stage glioblastoma trial
Jun 15Enrollment gets underway in Kazia's mid-stage lymphoma study
Jun 07Kazia, Pacific Pediatric Neuro-Oncology collaborate for paxalisib combo study in type of brain cancer
Dec 10Kazia Therapeutics -2% on cantrixil data in early-stage ovarian cancer study
Dec 09Kazia stock +22% on positive paxalisib data in glioblastoma
Nov 18Shareholder Returns
| KZIA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.8% | -3.3% | 1.9% |
| 1Y | -68.3% | 18.7% | 32.8% |
Return vs Industry: KZIA underperformed the US Biotechs industry which returned 18.7% over the past year.
Return vs Market: KZIA underperformed the US Market which returned 32.8% over the past year.
Price Volatility
| KZIA volatility | |
|---|---|
| KZIA Average Weekly Movement | 76.3% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KZIA's share price has been volatile over the past 3 months.
Volatility Over Time: KZIA's weekly volatility has increased from 41% to 76% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | n/a | John Friend | www.kaziatherapeutics.com |
Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.
Kazia Therapeutics Limited Fundamentals Summary
| KZIA fundamental statistics | |
|---|---|
| Market cap | US$9.72m |
| Earnings (TTM) | -US$10.71m |
| Revenue (TTM) | US$381.86 |
Over9,999x
P/S Ratio-0.9x
P/E RatioIs KZIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KZIA income statement (TTM) | |
|---|---|
| Revenue | AU$560.00 |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$560.00 |
| Other Expenses | AU$15.70m |
| Earnings | -AU$15.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.53 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,804,047.50% |
| Debt/Equity Ratio | 6.8% |
How did KZIA perform over the long term?
See historical performance and comparison